News stories about Lipocine (NASDAQ:LPCN) have been trending somewhat negative this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Lipocine earned a news sentiment score of -0.02 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 44.7038783270309 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- Interested In Lipocine Inc (NASDAQ:LPCN)? Here’s What Its Recent Performance Looks Like (finance.yahoo.com)
- 373,101 Shares in Lipocine Inc (LPCN) Purchased by Prosight Management LP (americanbankingnews.com)
- Lipocine Inc. (LPCN) stock returned 28.79% up – Monthly Gainer – The Stocks News (press release) (thestocksnews.com)
- Lipocine to Present at the 30th Annual ROTH Conference (finance.yahoo.com)
A number of research analysts have issued reports on LPCN shares. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Lipocine in a research note on Friday, December 8th. Canaccord Genuity cut Lipocine from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. Finally, Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $11.00 target price on shares of Lipocine in a research note on Thursday, January 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. Lipocine currently has a consensus rating of “Hold” and an average target price of $13.50.
ILLEGAL ACTIVITY WARNING: This news story was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3254063/somewhat-critical-news-coverage-somewhat-unlikely-to-impact-lipocine-lpcn-stock-price.html.
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.